NCT00725140

Standardized sTudy With Almotriptan in eaRly Treatment of Migraine

Standardized sTudy With Almotriptan in eaRly Treatment of Migraine, START. An International, Open-label, Single Arm, Effectiveness and Safety Study of Almotriptan in Primary Care Setting

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 501 (actual)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a observational, open, prospective, single arm cohort study within authorized SPC conditions to describe the effectiveness of Almotriptan in treating acute migraine attacks when pain is mild and in the first hour of pain in everyday primary care clinical practice.

Detailed description

Primary Objective: To describe the effectiveness of Almotriptan in treating acute migraine attacks when pain is mild and in the first hour of pain in everyday primary care clinical practice. Secondary Objectives: 1. Influence of an educational intervention on the early intake of the treatment 2. Influence of medication history or concomitant medication on treatment results 3. Influence of migraine triggers on treatment results 4. Influence of stress on treatment results 5. Tolerability profile validation 6. Patients' satisfaction 7. Reasons for delaying migraine treatment intake

Conditions

• Migraine

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-04-01
• Completion: 2009-07-01
• First posted: 2008-07-30
• Last updated: 2015-06-01

Locations

3 sites across 3 countries: France, Italy, Spain